Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more
Chimeric Therapeutics Limited (CHMMF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -2.343x
Based on the latest financial reports, Chimeric Therapeutics Limited (CHMMF) has a cash flow conversion efficiency ratio of -2.343x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.63 Million) by net assets ($1.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chimeric Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chimeric Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chimeric Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Sari Kreasi Boga Tbk
JK:RAFI
|
0.022x |
|
OHB - Dusseldorf Stock Exchang
DU:OHB
|
-0.102x |
|
Interbud-Lublin SA
WAR:ITB
|
-0.721x |
|
Bait Bakfar Ltd
TA:BKFR
|
0.014x |
|
Meadow Valley Corp
PINK:MVCO
|
-0.203x |
|
AIR PROD.&CHEMICALS - Dusseldorf Stock Exchang
DU:AP3
|
0.076x |
|
Hudson Resources Inc
PINK:HUDRF
|
-0.137x |
|
Kontigo Care AB
ST:KONT
|
0.046x |
Annual Cash Flow Conversion Efficiency for Chimeric Therapeutics Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Chimeric Therapeutics Limited from 2020 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $1.97 Million | $-7.28 Million | -3.685x | -20.75% |
| 2024-06-30 | $2.47 Million | $-7.54 Million | -3.052x | -5.87% |
| 2023-06-30 | $5.66 Million | $-16.32 Million | -2.882x | -463.33% |
| 2022-06-30 | $25.71 Million | $-13.15 Million | -0.512x | -45.42% |
| 2021-06-30 | $25.13 Million | $-8.84 Million | -0.352x | -166.12% |
| 2020-06-30 | $-63.91K | $-34.01K | 0.532x | -- |